BRCA 2 protein
Showing 1 - 25 of >10,000
Ovarian Tumors, BRCA1 Protein, BRCA2 Protein Trial in Worldwide (KU-0059436 (AZD2281)(PARP inhibitor))
Active, not recruiting
- Ovarian Neoplasms
- +2 more
- KU-0059436 (AZD2281)(PARP inhibitor)
-
Brussels, Belgium
- +4 more
Dec 19, 2022
Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma Trial (Nab paclitaxel,
Not yet recruiting
- Pancreatic Acinar Cell Carcinoma
- +6 more
- Nab paclitaxel
- +5 more
- (no location specified)
Oct 30, 2023
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)
Active, not recruiting
- BRCA1 Gene Mutation
- +5 more
- Durvalumab
- +3 more
-
Buffalo, New York
- +1 more
Jan 20, 2023
Breast Cancer Trial in Tucson, Albuquerque (Pegylated liposomal doxorubicin)
Completed
- Breast Cancer
- Pegylated liposomal doxorubicin
-
Tucson, Arizona
- +1 more
Jan 9, 2023
Triple Negative Breast Tumors, Triple Negative Breast Cancer, Breast Tumors Trial (Pembrolizumab, Paclitaxel, Carboplatin)
Not yet recruiting
- Triple Negative Breast Neoplasms
- +7 more
- Pembrolizumab
- +4 more
- (no location specified)
Aug 1, 2022
Germline Variant Carriers With BRCA1 or BRCA2
Recruiting
- BRCA1 and/or BRCA2 Variant Carriers
- +3 more
-
Okayama, JapanOkayama University
Dec 25, 2022
PREDICTION OF GERMLINE BRCA 1/2 GENES FROM HEALTHY OVARIES
Not yet recruiting
- BRCA Mutation
- +2 more
- Germinal BRCA
- (no location specified)
Mar 3, 2023
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
Recruiting
- Anatomic Stage III Breast Cancer AJCC v8
- +51 more
- Dostarlimab
- Niraparib
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Mar 15, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (Adavosertib)
Active, not recruiting
- Advanced Lymphoma
- +5 more
-
Philadelphia, PennsylvaniaECOG-ACRIN Cancer Research Group
Jun 28, 2022
BRCA and NACT in TNBC Patients
Completed
- Triple-Negative Breast Cancer
- BRCA1/2 genetic testing
-
Rome, RM, ItalyFondazione Policlinico Universitario Agostino Gemelli IRCCS
Feb 20, 2023
Breast Cancer, Genetic Predisposition Trial in Rome, Varese (Genetic predisposition to breast cancer)
Recruiting
- Breast Cancer
- Genetic Predisposition
- Genetic predisposition to breast cancer
-
Rome, Italy
- +1 more
May 4, 2023
Germline BRCA-mutated HER2-negative Breast Cancer Trial in Beijing (Camrelizumab+Fluzoparib)
Enrolling by invitation
- Germline BRCA-mutated HER2-negative Breast Cancer
-
Beijing, Beijing, ChinaBreast Cancer, Peking University People's Hospital
Nov 14, 2022
Breast Cancer, Genetic Disease, BRCA2 Mutation Trial (blood sample for BRCA2 mutation detection)
Not yet recruiting
- Breast Cancer
- +2 more
- blood sample for BRCA2 mutation detection
- (no location specified)
Jun 1, 2023
Breast Cancer, Metastatic Breast Cancer, BRCA1 Gene Mutation Trial in Boston (ABT-888, temozolomide)
Active, not recruiting
- Breast Cancer
- +3 more
-
Boston, Massachusetts
- +2 more
Dec 21, 2022
Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma Trial run by the National Cancer Institute (NCI)
Not yet recruiting
- Mesothelioma
- +5 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 1, 2023
Advanced Malignant Tumor, ATM Gene Mutation, BRCA1 Gene Mutation Trial in Houston (Laboratory Biomarker Analysis,
Active, not recruiting
- Advanced Malignant Neoplasm
- +7 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Feb 21, 2022
Breast Tumors Trial in Worldwide (KU-0059436 (AZD2281) (PARP inhibitor))
Completed
- Breast Neoplasms
- KU-0059436 (AZD2281) (PARP inhibitor)
-
West Hollywood, California
- +16 more
Jan 24, 2023
Ultra-rapid BRCA1/2 Status Screening Test in Theranostic
Not yet recruiting
- Breast Cancer
- Questionnaires
- Communication of the results of the BRCA1/2 ultra rapid test
- (no location specified)
Oct 26, 2023
Breast Cancer After Ovarian Cancer During and/or After Therapy:
Recruiting
- BRCA-Associated Breast Carcinoma
- Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).
-
Rome, RM, ItalyFondazione Policlinico Universitario Agostino Gemelli IRCCS
Mar 9, 2023
Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer Trial in United States (Niraparib, Dostarlimab)
Recruiting
- Stage I Breast Cancer
- +7 more
-
Baltimore, Maryland
- +6 more
Nov 11, 2022
BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer Trial in Providence (Talazoparib Oral Capsule)
Active, not recruiting
- BRCA1 Mutation
- +4 more
- Talazoparib Oral Capsule
-
Providence, Rhode Island
- +1 more
Nov 30, 2022
Breast Tumor Female Trial in United Kingdom (Digital Delivery of Pre-Genetic Testing Information via the BRCA-DIRECT Platform,
Active, not recruiting
- Breast Neoplasm Female
- Digital Delivery of Pre-Genetic Testing Information via the BRCA-DIRECT Platform
- Digital Delivery of Genetic Test Results via the BRCA-DIRECT Platform
-
Manchester, England, United Kingdom
- +4 more
Aug 12, 2022
Quality of Life Post Salpingo-oophorectomy in BRCA1/2 & PALB2
Recruiting
- Hereditary Breast and Ovarian Cancer
-
Barcelona, SpainHospital de la Santa Creu i Sant Pau
Jun 3, 2022